At a glance
ClinicalIndex Comparison Record- ✓Intima-media thickness of carotid artery >0.65 mm on ultrasound
- ✓Males aged 21–80 years, or women without child-bearing potential up to age 80
- ✓May continue stable concomitant aspirin, thiazide diuretics, calcium antagonists, or beta-blockers for hypertension
- ✓May remain on stable statin dose (unchanged for ≥2 months prior to enrollment)
- ✕ACE inhibitor or ARB use within previous 3 months
- ✕Initiation or change in statin dose within 2 months before study
- ✕Unable to return to Emory for follow-up blood draws and MR imaging
- ✕Premenopausal women with potential for pregnancy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Valsartan on Endothelial Function, Oxidative Stress, Carotid Atherosclerosis, and Endothelial Progenitor Cells (EFFERVESCENT)
In Brief
A Phase 2 clinical trial evaluating Valsartan and Placebo for Carotid Artery Diseases and Atherosclerosis. Completed, enrolled 120 participants across 1 site.
Detailed Summary
The EFFERVESCENT trial is designed to evaluate the effects of a specific ARB, called valsartan, on atherosclerosis. The investigators want to know if treatment with valsartan will increase the blood levels of markers responsible for repair of the vessel wall, reduce oxidation and inflammation, improve the function of the blood vessels, and arrest or slow down the progression of atherosclerosis over time.
Study Details
Timeline
Interventions
Valsartan was titrated to a target dose of 320 mg orally daily
A matched placebo pill will be given orally daily.